Shares of ADiTx Therapeutics, Inc. (NASDAQ:ADTX) fell 9% during mid-day trading on Wednesday . The company traded as low as $1.85 and last traded at $1.92. 1,235,533 shares changed hands during trading, a decline of 40% from the average session volume of 2,067,795 shares. The stock had previously closed at $2.11.
The business’s 50-day moving average is $2.85.
An institutional investor recently bought a new position in ADiTx Therapeutics stock. Hudson Bay Capital Management LP purchased a new stake in ADiTx Therapeutics, Inc. (NASDAQ:ADTX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 108,961 shares of the company’s stock, valued at approximately $551,000.
About ADiTx Therapeutics (NASDAQ:ADTX)
ADiTx Therapeutics, Inc, a life sciences company, focuses on developing nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients and address autoimmune diseases and allergies. The company commercializes Apoptotic DNA Immunotherapy (ADi), a nucleic acid-based technology that utilizes an approach, which mimics the way the body naturally induces tolerance to its own tissues.
See Also: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for ADiTx Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADiTx Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.